Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2003-10-31

Study Completion Date

2006-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine if orlistat (Xenical) therapy in overweight patients with NASH leads to enhanced weight loss over time, with subsequent improvement in the underlying necroinflammatory and fibrotic changes that are typical of NASH.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Previous studies have suggested that steady weight loss over time will result in improvement in aminotransferases, and more importantly, underlying histopathology in patients with NASH. A total of 50 biopsy-proven NASH patients will be enrolled in a prospective, randomized fashion. Twenty-five patients have been enrolled at the primary study site at Saint Louis University. Recruitment of the next 25 patients is taking place at a study subsite at Brooke Army Medical Center in San Antonio, Texas.

This will be an open-label study comparing an established weight loss program (1400-calorie diet with 30% fat) plus daily vitamin E (800 IU) and a daily multivitamin to the same weight loss program, daily vitamin E (800 IU) and multivitamin, plus orlistat (120 mg), three times daily for 36 weeks.

Data to be collected from prospective patients includes demographic information, such as age, sex, past medical history, medications, height and weight. Biochemical data to be collected from prospective patients includes liver enzymes, measures of insulin resistance to include, insulin levels, lipid panel, hemoglobin A1C, free fatty acids, complete blood count, coagulation studies, and vitamin E levels. Blood will also be collected and stored for markers of inflammation and fibrosis, such as C reactive protein and TNF-alpha. A liver biopsy will be obtained at the completion of the study for both histopathologic analysis and RNA analysis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fatty Liver Hepatitis

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

nonalcoholic steatohepatitis enzyme inhibitors lipase obesity insulin resistance

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Orlistat (Xenical)

Intervention Type DRUG

1400 kcal diet (30% fat)

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Liver biopsy obtained no more than 24 months before randomization with a pathology report confirming that the histological diagnosis is consistent with NASH
* Compensated liver disease with the following laboratory parameters at the entry visit:

* Hemoglobin values of greater than or equal to 12 gm/dl for females or 13 gm/dl for males
* WBC count \> 3,000/mm3
* Neutrophil count \> 1,500/mm3
* Platelets \> 70,000/mm3
* Albumin \>3.0 g/dl
* Serum creatinine \<1.4mg/dl
* Ability to give informed consent
* Alanine aminotransferase (ALT) greater than or equal to 40 U/L
* BMI \> or equal to 27 kg/m2
* Patients who receive orlistat must agree to participate in Xenicare, a free dietary counseling program provided by Roche (sponsor)

Exclusion Criteria

* Any cause for chronic liver disease other than NASH
* Evidence of decompensated liver disease such as a history of or presence of ascites, bleeding varices, or spontaneous encephalopathy
* History of alcohol consumption of greater than 20 grams per day in the past 2 years
* Prior surgical procedures to include gastroplasty, jejunoileal or jejunocolic bypass
* TPN within the past 6 months
* History of prior organ transplantation
* Concurrent enrollment in other experimental treatment protocols
* Use of ursodeoxycholic acid, rosiglitazone, pioglitazone, or metformin within the 6-month period before enrollment
* Women who are pregnant or breast-feeding

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Brent A Tetri, MD

Role: PRINCIPAL_INVESTIGATOR

St. Louis University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Saint Louis University

St Louis, Missouri, United States

Site Status

Brooke Army Medical Center

San Antonio, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA. Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial. Hepatology. 2009 Jan;49(1):80-6. doi: 10.1002/hep.22575.

Reference Type DERIVED

PMID: 19053049 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

XEN185

Identifier Type: -

Identifier Source: secondary_id

12458